Search hospitals > Ontario > TORONTO
Princess Margaret Cancer Centre
Claim this profileTORONTO, Ontario M5G 2M9
Global Leader in Cystic Tumor
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
Conducts research for Prostate Cancer
988 reported clinical trials
71 medical researchers
Summary
Princess Margaret Cancer Centre is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cystic Tumor, Cancer, Lung Cancer, Solid Tumors, Prostate Cancer and other specialties. Princess Margaret Cancer Centre is involved with conducting 988 clinical trials across 511 conditions. There are 71 research doctors associated with this hospital, such as Amit Oza, MD, Lillian Siu, MD, Marcus Butler, and Philippe Bedard.Area of expertise
1Cystic Tumor
Global LeaderStage IV
Stage III
EGFR positive
2Cancer
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Amit Oza, MDPrincess Margaret Cancer Centre5 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
30 reported clinical trials
50 drugs studied
Lillian Siu, MDPrincess Margaret Cancer Centre6 years of reported clinical research
Studies Solid Tumors
Studies Breast Cancer
18 reported clinical trials
42 drugs studied
Marcus ButlerPrincess Margaret Cancer Centre8 years of reported clinical research
Studies Melanoma
Studies Ovarian Cancer
15 reported clinical trials
27 drugs studied
Philippe BedardPrincess Margaret Cancer Centre3 years of reported clinical research
Studies Breast Cancer
Studies Cystic Tumor
16 reported clinical trials
27 drugs studied
Clinical Trials running at Princess Margaret Cancer Centre
Breast Cancer
Lung Cancer
Multiple Myeloma
Ovarian Cancer
Lymphoma
Non-Small Cell Lung Cancer
Cancer
Solid Tumors
Colorectal Cancer
Plasma Cell Neoplasm
Sacituzumab Tirumotecan + Pembrolizumab
for Breast Cancer
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.
Recruiting2 awards Phase 33 criteria
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
PF-07220060 + Letrozole
for Breast Cancer
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Princess Margaret Cancer Centre?
Princess Margaret Cancer Centre is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cystic Tumor, Cancer, Lung Cancer, Solid Tumors, Prostate Cancer and other specialties. Princess Margaret Cancer Centre is involved with conducting 988 clinical trials across 511 conditions. There are 71 research doctors associated with this hospital, such as Amit Oza, MD, Lillian Siu, MD, Marcus Butler, and Philippe Bedard.
Where is Princess Margaret Cancer Centre located?
**Princess Margaret Cancer Centre Location and Access:**
- **Address:** 610 University Ave, Toronto, ON M5G 2M9.
- **Public Transport:** Accessible via Queen's Park subway station on Line 1, 506 Carlton or 505 Dundas streetcars. The 142 bus provides additional service along University Avenue during rush hours.
- **Drop-off Points:** Murray Street entrance and University Avenue entrance, both wheelchair accessible.
Who should I call to ask about financial aid or insurance network?
The Princess Margaret Cancer Centre offers comprehensive financial assistance and insurance support for patients through various programs:
- **Income Assistance Programs**: Patients can consult a social worker or contact the Psychosocial Oncology clinic at 416-946-4525.
- **Canadian Breast Cancer Support Fund**: Provides up to $1000 for expenses such as transportation, parking, food, home health, prosthetics, supportive care, and rent.
- **Kelly Shires Breast Cancer Foundation**: Offers up to $1000 for similar expenses to those diagnosed with breast cancer.
- **Canadian Cancer Society’s Travel Treatment Fund**: Assists with travel costs based on a financial assessment.
- **Wellspring's Money Matters**: Connects patients with financial counselling for income replacement and drug compensation.
- **Power of Hope Cost Reduction Program**: Aids cancer patients under 40 with fertility preservation treatment costs.
- **POGO Financial Assistance Program**: Supports Ontario families with expenses like accommodation, food, and child care for siblings under 12 during the child's cancer treatment.
- For general inquiries, contact The Princess Margaret Cancer Foundation at 416-946-6560 or toll-free at 1-866-224-6560.
What insurance does Princess Margaret Cancer Centre accept?
The Princess Margaret Cancer Centre accepts Canadian insurance plans, including OHIP and private insurance. OHIP covers most cancer treatment costs, while some expenses might need coverage through private insurance, government programs, or income tax claims. International patients should refer to the UHN International Patient Program (IPP), and private cancer care services may require a referral and can be covered by private insurance or self-pay.
What awards or recognition has Princess Margaret Cancer Centre received?
The Princess Margaret Cancer Centre, located in Toronto, Ontario, is among the top five cancer research centers globally, renowned for its groundbreaking research and exceptional patient care. It boasts a comprehensive clinical trials program, offering numerous trials for different cancer types, with its database frequently updated. The center's innovative work and life-saving research are supported by the Invest in Research program, enhancing its capability to transform patient outcomes worldwide.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.